broadwww.gogo.com

www.gogo.com  时间:2021-03-20  阅读:()
EditorialTheEUGOGOConsensusStatementontheManagementofGraves'Orbitopathy:EquallyApplicabletoNorthAmericanCliniciansandPatientsTheEuropeangrouponGraves'orbitopathy(EUGOGO;www.
eugogo.
org)isamultidisciplinaryconsortiumofclinicianscommittedtoimprovingtheman-agementofpatientswiththeocularcomplicationsofGraves'disease.
ThegroupdevelopedaconsensusstatementonthemanagementofGraves'orbitopathy(GO)thatwasunveiledattheannualmeetingoftheEuropeanThyroidAssociationinLeipzig,Germany,inSeptember2007,andsimultane-ouslyappearsinthisissueofThyroidandintheEuropeanJournalofEndocrinology(1).
EUGOGOistobecommendedfortheireffortsthatreectaremarkabledegreeofinterna-tionalcooperationbyacademicendocrinologistsandoph-thalmologists.
Theauthorsrefertothedocumentasa''consensusstate-ment''byexpertsintheeld,ratherthanapracticeguideline.
Thisseemsappropriate,becausewhiletheEUGOGOgroupcanbecreditedwithhavingperformedthemajorityofran-domizedcontrolledtrials(RCTs)inthisarea,theyarenotofsufcientscopetosupportformalpracticeguidelines.
De-spitethis,thedocumentistimelyandshouldproveusefultoclinicianswhomanageGOpatients.
Theauthorsrightlyanticipatethatthedocumentwill''provideafocusforauditandresearch''andaidintheidenticationoftopicsforfutureRCTs.
Theconsensusstatementisscholarlyandconcise,andtherecommendationsaregenerallyapplicabletoNorthAmeri-can,aswellasEuropean,cliniciansandpatients.
Thegradedrecommendationsareappendedinthedocument,andtheevidencesupportingeachisdiscussedindetailinthebodyofthetext.
TheapplicationoftherecommendationsrequiresthatcliniciansmustrstsegregatetheirGOpatientsinto''mild,''''moderatetosevere,''or''sight-threatening''categories,anddeterminewhetherornotthediseaseisactive.
Sufcientde-tailsareprovidedwithinthetextregardingtheassessmentofdiseaseseverityandactivitytoallowclassicationintothesebroadcategories.
EUGOGOdoesnotadvocateusinganyde-tailedgradingorscoringsystemotherthantherelativelysimple''clinicalactivityscore''andspecicocularmeasure-mentstoassesstheseverityofthedisease.
Whilethisapproachmaynotideallycaptureallfeaturesofthedisease,ithasbeenvalidatedbythegroupinnumerousclinicalstudiesandshouldserveasthegoldstandardagainstwhichotherGOclassica-tionsystemsaremeasured.
ThedocumentwillserveasanespeciallyusefultoolforclinicianswhoalreadyhavesomeexpertiseinmanagingGOpatients.
OthersnotsoexperiencedbutencounterGOpa-tientsintheirpracticeareadvisedto''referpatientswithGO,exceptforthemildestcases,tocombinedthyroid–eyeclinicsforfurtherassessmentandmanagement.
''Whichreferralsshouldbemadeurgentlyandwhicharenonurgentiscare-fullyoutlinedinthetext.
TheproblematicaspectofthisrecommendationforcliniciansinNorthAmerica,however,isthatregionalGOconsultantsarefrequentlyophthalmolo-gistswhodonotworkincombinedthyroid–eyeclinics.
OneofthemanypositiveresultsstemmingfromtheinceptionofEUGOGOhasbeenthemandatoryestablishmentofacom-binedthyroid–eyeclinicwithineachoftheEuropeanmedicalcenterwishingtoparticipateintheconsortium.
OnlythroughthistypeofcooperationcanGOpatientsbenetfromthefullrangeofexpertiseneededtounderstandandmanageallaspectsofthisperplexingdisease.
Whilethevastmajorityoftherecommendationsseemtometobequitereasonableandbasedtotheextentpossibleonpertinentliterature,Idotakeissuewiththestatementthat''thetreatmentofchoiceformoderatetosevereandactiveGOispulsesofintravenousglucocorticoids(GCs).
''WhilesevereGOmaywarrantthisapproach,IremainreluctanttorecommendivGCstopatientswithonlymoderatedisease(i.
e.
,thosehavingonlyasinglefeaturethatwouldplacetheminthe''moderatetosevere''category,orafewfeaturesmeasuringjustabovemild).
MyconcernstemsbothfromreportsoffatalacuteliverfailureinfourGOpatientsduringorfollowingcompletionofivGCtreatment(2,3),andfromthenaturalhistoryofthediseaseshowingimprovementinthemajorityof(albeitunselected)patientswithinayears'time.
Fortunately,thefrequencyofhepatotoxicityappearstobeverylow;7ofapproximately800GOpatientstreatedinItalywithivGCssufferedsevereliverdamage,ofwhom3died(3).
BecausenocaseofliverfailurehasbeenreportedinGOpatientsreceiving<8gmethylprednisolone,thecon-sensusstatementindicatesthatthecumulativedoseinonecourseshouldbelessthanthisamountandspeciesthativGCsshouldonlybeadministeredincentersexperiencedinthistherapy.
Despitethis,therisk–benetratioforivGCsinpatientswithactivediseaseofonlymoderateseveritywhomightdoequallywellwithoralsteroidsorevencarefulTHYROIDVolume18,Number3,2008MaryAnnLiebert,Inc.
DOI:10.
1089=thy.
2008.
0034281observationandfrequentreassessmentseemstometobeweightedtowardthesideofunacceptablerisk.
Insummary,theconsensusstatementbyEUGOGOisatimelyandusefuldocumentthatcanbeupdatedasadditio-nalevidencefromfutureRCTsbecomesavailable.
TheEu-ropeangroupisproceedingwithmulticentertrialsthatwillallowrecruitmentoflargenumbersofpatientsintothesestudies.
Thisconsensusstatementbringstotheforeashort-cominginthecareofGOpatientsintheUnitedStates,namely,thatmanypatientsarenotcaredforinjointthyroid–eyeclinics.
Inaddition,endocrinologists,ophthalmologists,andotherswhoseeGOpatientsinthiscountryarenotyetorganizedtoperformmulticenterRCTs.
Thereis,how-ever,activityunderwaytoincreasecooperationbetweenthesegroupsandtoestablishtheimportantinfrastructureneededtoperformlargemulticenterGOtrialsinNorthAmerica.
Finally,whileevidence-basedguidelinesorconsensusstatementscanfacilitatedecisionmaking,managementmustbeultimatelyindividualizedandfocusedontheneedsanddesiresofthepatient.
Thisrequirestheapplicationofboththeartandscienceofmedicine,anddemandsthatthecli-nicianactivelylistenstoGOpatients,manyofwhomareunderstandablyapprehensiveandfrightened.
Compassio-natecounselingofpatientshouldincludewiderangingdis-cussionsonthenatureoftheconditionanditsnaturalhistory,aswellascustomizedtreatmentoptions.
Suchanapproachislikelytoimproveoutcomesofwhatisoftenahighlydistressingdisease.
References1.
BartalenaL,BaldeschiL,DickensonA,EcksteinA,Kendall-TaylorP,MarcocciC,etal.
2007ConsensusstatementoftheEuropeanGrouponGraves'Orbitopathy(EUGOGO)onthemanagementofGraves'orbitopathy.
Thyroid18:333–346.
2.
WeisselM,HauffW2000Acuteandfatalliverfailureafterhigh-doseglucocorticoidpulsetherapyinapatientswithsevereeyedisease.
Thyroid10:521.
3.
MarinoM,MorabitoBrunetteMR,BartalenaL,PincheraA,MarcocciC2004AcuteandsevereliverdamageassociatedwithintravenousglucocorticoidpulsetherapyinpatientswithGraves'ophthalmopathy.
Thyroid14:403–406.
—RebeccaBahn,M.
D.
President,AmericanThyroidAssociationConsultantinEndocrinology,MayoClinic282BAHN

美国Cera 2核4G 20元/45天 香港CN2 E5 20M物理机服务器 150元 日本CN2 E5 20M物理机服务器 150元 提速啦

提速啦 成立于2012年,作为互联网老兵我们一直为用户提供 稳定 高速 高质量的产品。成立至今一直深受用户的喜爱 荣获 “2021年赣州安全大赛第三名” “2020创新企业入围奖” 等殊荣。目前我司在美国拥有4.6万G总内存云服务器资源,香港拥有2.2万G总内存云服务器资源,阿里云香港机房拥有8000G总内存云服务器资源,国内多地区拥有1.6万G总内存云服务器资源,绝非1 2台宿主机的小商家可比。...

易探云2核2G5M仅330元/年起,国内挂机宝云服务器,独立ip

易探云怎么样?易探云是国内一家云计算服务商家,致力香港服务器、国内外服务器租用及托管等互联网业务,目前主要地区为运作香港BGP、香港CN2、广东、北京、深圳等地区。目前,易探云推出深圳或北京地区的适合挂机和建站的云服务器,国内挂机宝云服务器(可选深圳或北京地区),独立ip;2核2G5M挂机云服务器仅330元/年起!点击进入:易探云官方网站地址易探云国内挂机宝云服务器推荐:1、国内入门型挂机云服务器...

无忧云:服务器100G高防云服务器,bgpBGP云,洛阳BGP云服务器2核2G仅38.4元/月起

无忧云怎么样?无忧云值不值得购买?无忧云,无忧云是一家成立于2017年的老牌商家旗下的服务器销售品牌,现由深圳市云上无忧网络科技有限公司运营,是正规持证IDC/ISP/IRCS商家,主要销售国内、中国香港、国外服务器产品,线路有腾讯云国外线路、自营香港CN2线路等,都是中国大陆直连线路,非常适合免备案建站业务需求和各种负载较高的项目,同时国内服务器也有多个BGP以及高防节点。目前,四川雅安机房,4...

www.gogo.com为你推荐
12306崩溃为什么12306进不去www.jjwxc.net有那个网站可以看书?钟神发战旗TV ID:新年快乐丶未央不见是哪个主播百度关键词工具百度有关键字分析工具吗?Google AdWords有的www.33xj.compro/engineer 在哪里下载,为什么找不到下载网站?www.niuav.com给我个看电影的网站www.kaspersky.com.cn现在网上又有病毒了?关键词分析怎么样分析关键词?彪言彪语()言() 语雀嘴鳝雀鳝鱼嘴巴变红甚么缘由
三级域名网站 过期域名抢注 namecheap 鲜果阅读 debian源 台湾谷歌地址 秒杀预告 域名转接 tna官网 爱奇艺vip免费领取 东莞服务器 流媒体加速 华为云服务登录 网站加速软件 东莞服务器托管 贵阳电信测速 塔式服务器 windowsserver2012 建站行业 asp.net虚拟主机 更多